Buy Rating for Scholar Rock Holding: Promising Clinical Advancements and Strategic Focus Highlighted by Phase 2 EMBRAZE Trial Results

Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) and keeping the price target at $50.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Scholar Rock Holding’s promising clinical advancements and strategic focus. The recent Phase 2 EMBRAZE trial results demonstrated that apitegromab, when combined with tirzepatide, significantly preserved lean muscle mass in obese and overweight patients, a critical advantage over existing GLP-1 agonists known for muscle loss. This preservation of lean tissue, with approximately 85% of weight loss attributed to fat, positions apitegromab as a leading candidate for quality weight management.
Furthermore, the safety profile of apitegromab was favorable, with fewer treatment discontinuations compared to tirzepatide alone, and no serious adverse events linked to its use. This contrasts sharply with competing therapies, enhancing apitegromab’s appeal. Scholar Rock’s commitment to leveraging its latent myostatin platform for both weight management and rare neuromuscular disorders underscores its potential for long-term growth, supporting Maldonado’s positive outlook on the stock.

In another report released on June 18, BMO Capital also maintained a Buy rating on the stock with a $57.00 price target.